X0306 4 2014-12-17 0 0000890465 NPS PHARMACEUTICALS INC NPSP 0001192128 BESHAR LUKE M 550 HILLS DRIVE BEDMINSTER NJ 07921 0 1 0 0 EVP & CFO Common Stock 2014-12-17 4 M 0 11500 3.34 A 84280 D Common Stock 2014-12-17 4 M 0 8906 8.21 A 93186 D Common Stock 2014-12-17 4 M 0 31852 8.23 A 125038 D Common Stock 2014-12-17 4 S 0 52258 35.00 D 72780 D Employee Stock Options (right to buy) 3.34 2014-12-17 4 M 0 11500 0 D 2020-02-19 Common Stock 11500 9189 D Employee Stock Options (right to buy) 8.21 2014-12-17 4 M 0 8906 0 D 2022-02-07 Common Stock 8906 17813 D Employee Stock Options (right to buy) 8.23 2014-12-17 4 M 0 31852 0 D 2023-02-13 Common Stock 31852 53089 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. On February 19, 2010, the Reporting Person received a grant of 40,000 stock options under NPS Pharmaceuticals, Inc.'s (the "Issuer") 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. As of the date of this filing, the performance criteria and the time-based criteria for 31,812 of these options has been satisfied. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant. On February 7, 2012, the Reporting Person received a grant of 47,500 stock options under the Issuer's 2005 Omnibus Incentive Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. On February 13, 2013, the Reporting Person received a grant of 84,941 stock options under the Issuer's 2005 Omnibus Incentive Plan. The options become exercisable based on the following vesting schedule: 25% on the first anniversary of the grant and 6.25% every three months thereafter. /s/ Luke M. Beshar, by Jill Thompson as attorney-in-fact 2014-12-18